VolitionRX (NYSEAMERICAN:VNRX) Announces Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) issued its earnings results on Thursday. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.15), FiscalAI reports. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million.

VolitionRX Trading Down 5.7%

NYSEAMERICAN VNRX traded down $0.04 on Thursday, hitting $0.63. 830,161 shares of the company traded hands, compared to its average volume of 471,434. The business’s 50 day moving average price is $1.19 and its 200-day moving average price is $2.79. VolitionRX has a 52-week low of $0.60 and a 52-week high of $15.10. The company has a market capitalization of $5.44 million, a price-to-earnings ratio of -0.15 and a beta of 1.16.

Analyst Upgrades and Downgrades

Several research firms recently commented on VNRX. Citigroup cut VolitionRX to a “hold” rating in a research report on Monday, April 20th. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Maxim Group reaffirmed a “buy” rating and issued a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Finally, Benchmark reiterated a “hold” rating on shares of VolitionRX in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in VolitionRX during the 4th quarter worth approximately $28,000. Virtu Financial LLC boosted its position in shares of VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of VolitionRX in the fourth quarter worth $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRX during the 2nd quarter valued at $52,000. Finally, Citadel Advisors LLC lifted its stake in shares of VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.